Table 5.
The main clinical and demographic features of Group C: EGF and DGF patients.
| Group C (%) | EGF (%) | DGF (%) | P | |
|---|---|---|---|---|
| n. | 252 | 126 | 126 | |
| Age (years) | 47.3 ± 10.1 | 46.8 ± 11.0 | 47.8 ± 9.3 | 0.4 |
| Gender (M/F) | 161 (63.9)/91 (36.1) | 80 (63.5)/46 (36.5) | 81 (64.3)/45 (35.7) | 0.9 |
| Dialysis (HD/PD) | 232 (92.1)/20 (7.9) | 109 (86.5)/17 (13.5) | 123 (97.6)/3 (2.4) | 0.0006 |
| Dialysis vintage (years) | 6.8 ± 4.5 | 5.9 ± 4.1 | 7.7 ± 4.8 | 0.008 |
| HCV+ (n,%) | 56, 22.2 | 22, 17.4 | 34, 26.9 | 0.07 |
| Body mass index (BMI) (kg/m2) | 24.2 ± 3.6 | 23.5 ± 3.3 | 24.8 ± 3.9 | 0.007 |
| Panel reactive antibodies (%) | 7.0 ± 5.1 | 7.5 ± 5.9 | 7.3 ± 6.7 | 0.9 |
| Cold ischemia time (hours) | 13.1 ± 5.4 | 13.0 ± 5.3 | 13.2 ± 5.5 | 0.8 |
| Mismatches (n) | 3.4 ± 0.9 | 3.3 ± 0.9 | 3.5 ± 0.9 | 0.1 |
| Cyclosporine (n) | 15 (5.9) | 19 (15.1) | 19 (15.1) | 1 |
| Tacrolimus (n) | 214 (84.9) | 107 (84.9) | 107 (84.9) | 1 |
| mTOR inhibitors (n) | 2 (0.8) | 2 (1.5) | 2 (1.5) | 1 |